Compare Salesforce Inc (CRM) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs CVS Health Corp — how do they compare? Salesforce Inc trades at $196.95 (market cap $161.76B), while CVS Health Corp trades at $93.65 (market cap $122.36B). The key difference: Salesforce Inc is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CRM | CVS | |
|---|---|---|
Market Cap | $161.76B | $122.36B |
Sector | Technology | Health |
52-Week High | $266.23 | $110.60 |
52-Week Low | $150.12 | $65.51 |
Enterprise Value | $191.81B | $184.71B |
Dividend Yield | 0.89% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.51, up 2.47% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.88 exceeding expectations of $3.13. Revenue growth accelerated to $37.90 billion in 2025, while net income margin improved to 16.35%. Analyst consensus remains strongly bullish with a $230.61 price target.
Outlook: Salesforce demonstrates robust fundamentals with high profitability and consistent earnings outperformance, supported by AI monetization growth. Risks include competitive pressures in SaaS and macroeconomic volatility affecting tech stocks. The stock offers potential upside to analyst targets if execution continues.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
